Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 208-874-7 | CAS number: 544-62-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Skin sensitisation
Administrative data
- Endpoint:
- skin sensitisation: in vitro
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2019
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 019
- Report date:
- 2019
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- other: Genomic Allergen Rapid Detection (GARDTM)
- Version / remarks:
- currently under ECVAM validation.
- Principles of method if other than guideline:
- please see documentation attached regarding GARD skin test.
It is a new test currently under validation with ECVAM/OECD.
Genomic Allergen Rapid Detection (GARDTM) is an in vitro assay designed to predict the ability of chemical substances to induce skin sensitisation based on the analysis of the relative expression levels of a biomarker signature of 196 genes using a human myeloid leukemia cell line called SenzaCell. The GARDTM is based on chemical stimulation of the SenzaCell line, acting as an in vitro model of human Dendritic Cells (DCs). The readout of the assay is a transcriptional quantification of the genomic predictors, collectively termed the GARDTM Prediction Signature (GPS), using Nanostring nCounter technology. - GLP compliance:
- yes (incl. QA statement)
- Type of study:
- activation of dendritic cells
Test material
- Reference substance name:
- Batilol
- EC Number:
- 208-874-7
- EC Name:
- Batilol
- Cas Number:
- 544-62-7
- Molecular formula:
- C21H44O3
- IUPAC Name:
- 3-(octadecyloxy)propane-1,2-diol
- Test material form:
- solid: particulate/powder
Constituent 1
- Specific details on test material used for the study:
- Batch No.: 8462
Purity: approx. 99 %
Physical State: solid (powder)
Colour: white to pale yellow
Stability: stable
Storage Conditions: room temperature, protected from light
Expiry Date: 10.07.2021
Safety Precautions: The routine hygienic procedures will be sufficient to assure personnel health and safety.
In vitro test system
- Details on the study design:
- Preparation of the test item:
the test item is dissolved in either dimethyl sulfoxide (DMSO), water or in a different suitable solvent
Test system:
FACS:
FACS: BD Canto II
Software: BD FACS DIVA 6.0
Voltage Settings: FSC: 129 V, SSC: 435 V, FITC: 290 V, PE/PI: 315 V
Threshold value of FSC: 5000
Compensation: PI – 21.09 % FITC, FITC – 1.41 % PI
Cell line:
Human myeloid leukemia cell line Senza cells, provided by SenzaGen AB.
Cells tested routinely for mycoplasma, were seeded in culture medium at an appropriate density and sub-cultured at least 2 weeks before the test.
Only cells at a low passage number (<16) were used.
Cells are cultured in 175cm2 culture flasks (Greiner) in MEM/Alpha Modification with L-glut, Ribo-Deoxyribo (Thermo Scientific; Cat. No.: SH30265.01) supplemented with 20% fetal bovine serum (FBS, Gibco Life Science, Cat No.: 10270-106) (= semi-complete medium), and freshly added 40 ng/mL GM-CSF (Miltenyi Biotec, Cat No.: 130-093-868) in a humidified incubator at 37 ± 1°C and 5% CO2 (complete medium).
Dose groups:
Medium Control: semi-complete medium
Solvent Control: 0.1% (v/v) for DMSO or a different solvent for the test item and the positive control
Positive Control: 75 μM p-Phenylenediamine (CAS : 106-50-3)
Test Item:
Input finder: 9 concentrations of the test item down to 1 mM stock solution
Main stimulation: 1 concentration, which will lead to a cell viability of 90 ± 5%
Experimental procedure:
pre-test:
Nine concentrations (stock solutions) down to 1 mM were prepared. (i.e. 500 mM – 400 mM – 300 mM – 200 mM – 100 mM – 50 mM – 10 mM – 5 mM – 1 mM). These stock solutions were further diluted 100-fold into semi-complete medium giving the stock B solutions.
Highest concentration tested: 500µM.
Main test:
A stock solution of the positive control (75 mM) in DMSO and a stock solution 1000-fold higher as the GARD input concentration of the test item in the solvent determined in the solvent finding pre-experiment were freshly prepared immediately before use.
The stock solution of the positive control, pure DMSO as a negative control, the stock solution of the test item and the solvent of the test item were diluted 100-fold into semi-complete medium (= Stock B) to achieve the in-well concentration of 0.1% DMSO.
For testing, SenzaCells were pre-cultured for at least 72 h - 96 h in culture flasks at a cell density of 0.2 x 10^6 cells/mL. Prior to test item application, cells were harvested from the cell culture flask by centrifugation and were re-suspended in fresh semi-complete medium at a density of 2.22 x 10^5 cell/mL. Then 3.6 mL of cell suspension were seeded into a 12 well plate-bottom plate (2 x 10^5 cells/well).
The stock B solutions of the positive control, the solvent control of the test item input concentration and the solvent of the test item were mixed 1:10 (v/v) with the cell suspension prepared in the 12-well plate. Treated plates were incubated for 24 h ± 0.5 h at 37 °C ± 1 °C and 5% ± 0.5% CO2.
The cells were stained to check the quality of the cells.
After 24 h ± 0.5 h of exposure, 1 mL of the cells were transferred three times into small reaction tubes and further 500 μL were transferred twice into two FACS tubes. The cells of the reaction tubes were collected by centrifugation (approx. 300 x g), re-suspended in 500 μL TRIzol and frozen at < -20 °C. The cells of the FACS tubes were washed twice with FACS buffer. After washing, cells were re-suspended in 50 μL propidium iodide (PI) solution (1 μg/mL) in FACS buffer. Cells were stained for approx. 10 minutes at 2-8 °C in the dark. After staining, cells were washed with FACS buffer again and will be re-suspended in 200 μL FACS buffer.
The PI uptake of the cells (as an indicator of cytotoxicity) was analysed immediately after the staining procedure by flow cytometry using an excitation wavelength of λ = 488 nm and an emission wavelength of λ > 650 nm. A total of 10.000 living (PI negative) cells were acquired and cell viability will be calculated for each sample according to the following equation:
Rv = (Vs/Vc)X100
where: Rv = Relative viability of the sample in %
Vs = Absolute viability of the sample in %
Vc = Absolute viability of the mean of the two unstimulated control samples in %
RNA isolation:
The first tube of each TRIzol sample triplicates was thawed slowly on ice. The samples were centrifuged to remove particulate debris and the supernatant was transferred into new tubes. An equal volume of 95% - 100% ethanol was added and the whole mixture was transferred on the column of a Zymo-SpinTM IIC Columns (ZymoResearch Cat.R5052).
The flow through was discarded and the column was washed twice with 400 μL with the Direct-zolTM RNA PreWash. The flow through was discarded again. After the pre-washing step the column was washed with 700 μL RNA wash buffer. The flow through was discarded again and the column was placed in a new RNAse-free tube. The RNA was eluted with 25 μL RNAse-free water. After centrifugation the collected RNA was transferred on the column again to elute the whole RNA. The RNA was stored at -80 °C for shipment.
Endpoint Measurement (at Test Side 1)
1/RNA Quality Control
The RNA quality and quantity was measured with an Agilent 2100 BioAnalyser. If the RNA sample did not pass the quality control criteria (see section 11.3) the RNA had to be isolated from the last two TRIzol samples and quality had to be measured again.
RNA samples which had passed the criteria undergo Nanostring endpoint measurement with an appropriate code set for GARD skin.
2/ Nanostring Hybridisation
All hybridization samples were use a total RNA concentration of 100 ng.
All RNA samples were diluted to 20 ng/μL with RNA-free water to use 5 μL of each for hybridization.
For hybridization mix 8 μL of the master mix (provided in the Nanostring master kit), 5 μL RNA sample (20 ng/μL) and 2 μL of the capture code set were mixed. The whole approach was incubated in a thermocycler at 65 °C for 24 h ± 0.5 h.
3/ Setting up the Nanostring Preparation and Measurement
The nCounter Prepstation (Nanostring) was prepared as described in the manual. After hybridization the samples were removed from the thermocycler and spinned down before opening. The samples were placed in the nCounter Prepstation, too. The preparation of the nanostring cartridges took around 3 hours.
The cartridges were analysed by an nCounter Digital Analyser (Nanostring).
Results and discussion
In vitro / in chemico
Results
- Key result
- Run / experiment:
- mean
- Parameter:
- other: Mean decision value
- Value:
- -1.2
- Vehicle controls validity:
- not applicable
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Remarks on result:
- no indication of skin sensitisation
- Other effects / acceptance of results:
- All the acceptance criteria are met for the BioAnalyser and Nanostring measurement.
Any other information on results incl. tables
Prediction for skin sensitization:
The prediction is defined as described below:
- If the mean decision value (DV) of biological replicate samples is ≥0, the substance is classified as a sensitizer
If the mean decision value (DV) of biological replicate samples is <0, the substance is classified as anon-sensitizer
Results table:
Negative Control |
Positive Control |
BATILOL |
||
Decision Values |
Main Stimulation |
Decision Values |
Main Stimulation |
Decision Values |
-1.57 |
1 |
10.17 |
1 |
-0.97 |
-1.56 |
2 |
9.37 |
2 |
-1.35 |
-1.99 |
3 |
9.1 |
3 |
-1.28 |
-1.71 |
Mean |
9.55 |
Mean |
-1.20 |
Predicition |
||||
negative |
positive |
negative |
Applicant's summary and conclusion
- Interpretation of results:
- GHS criteria not met
- Executive summary:
The sensitization potential of the test substance was performed according to the GARD assay (It is a new test currently under validation with ECVAM/OECD). Genomic Allergen Rapid Detection (GARDTM) is an in vitro assay designed to predict the ability of chemical substances to induce skin sensitisation based on the analysis of the relative expression levels of a biomarker signature of 196 genes using a human myeloid leukemia cell line called SenzaCell. The GARDTM is based on chemical stimulation of the SenzaCell line, acting as an in vitro model of human Dendritic Cells (DCs). The readout of the assay is a transcriptional quantification of the genomic predictors, collectively termed the GARDTM Prediction Signature (GPS), using Nanostring nCounter technology.)
In this study under the given conditions the test item did not change the genomic profile of the cells for sensitisation in at least three independent experiment runs. Therefore, the test item might be considered as non-sensitiser.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.